Abstract:Multiple sclerosis (MS) is an autoimmune, demyelinating, degenerative disease of the central nervous system. Secondary progressive (SP) MS differs from relapse-remitting (RR) MS in clinical symptoms and histopathology. As disease progresses, the proportion of B cells and plasma cells increases in the brain. Moreover, meningeal tertiary lymphoid structures (TLS) are present in a large proportion of SPMS patients and are associated with more severe pathology. Treatment is available for suppressing relapses in RRMS, but no disease modifying therapy (DMT) is available for the ongoing disease worsening in SPMS. This is, in part, due to a lack of preclinical models for SPMS. There is a need for rodent models of SPMS to investigate disease mechanisms and treatment options. This thesis describes the development of two new rodent models of SPMS, characterised by glial activation, lymphocyte infiltration, demyelination, and neuronal death behind a closed blood-brain barrier (BBB). Focal MS-like lesions were induced by first immunising mice with MOG and CFA intradermally, followed by an intracranial injection with heat-killed mycobacterium tuberculosis in either the striatum or the piriform cortex. Mice were treated with anti-LINGO-1 or anti-CD20 antibodies 4 weeks after initiation of the lesion. Treatment effects on the different aspects of the focal lesions were evaluated by immunohistochemistry. MS-like lesions formed in the brains independent of injection site. However, TLS were only formed in mice with lesions in the piriform cortex. Both types of lesions continued to grow over time. Anti-LINGO-1 therapy promoted oligodendrocyte survival and reduced glial activation in the brains of these mice. Treatment with anti-CD20 decreased the extent of glial activation, significantly decreased the number of B and T lymphocytes, and reduced the size of the TLS. SPMS with and without TLS can be modelled in rodents, with lesions that continue to evolve over time behind an intact BBB. Two different treatments were shown to be effective in this model, demonstrating the potential of using anti-LINGO-1 or anti-CD20 as a DMT for SPMS.

Multiple sclerosis animal models: a clinical and histopathological perspective

The Development of a New Model of Progressive Multiple Sclerosis

Characterization of pathological stages in a mouse model of progressive multiple sclerosis

What do animal models tell us about the role of EBV in the pathogenesis of multiple sclerosis?

Pre-clinical and Clinical Implications of “Inside-Out” vs. “Outside-In” Paradigms in Multiple Sclerosis Etiopathogenesis

The contribution of neuropathology to multiple sclerosis research

Autophagy Modulation in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis.

Towards Treating Multiple Sclerosis Progression

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis.

Cellular architecture of evolving neuroinflammatory lesions and multiple sclerosis pathology

Remyelination therapies for multiple sclerosis: optimizing translation from animal models into clinical trials

Modulation of Multiple Sclerosis and Its Animal Model Experimental Autoimmune Encephalomyelitis by Food and Gut Microbiota

Ectopic Lymphoid Follicles in Progressive Multiple Sclerosis: from Patients to Animal Models.

An Overview of Multiple Sclerosis In Vitro Models

The roles of macrophages and microglia in multiple sclerosis and experimental autoimmune encephalomyelitis

Gut microbiota in multiple sclerosis and animal models

A B Cell-Driven Autoimmune Pathway Leading to Pathological Hallmarks of Progressive Multiple Sclerosis in the Marmoset Experimental Autoimmune Encephalomyelitis Model

A novel in vitro model for investigating oligodendroglial maturation and myelin deposition under demyelinating and remyelinating conditions: Impact of microglial depletion and repopulation

Dietary factors in experimental autoimmune encephalomyelitis and multiple sclerosis: A comprehensive review

Immunopathogenesis of multiple sclerosis: molecular and cellular mechanisms and new immunotherapeutic approaches

The neuropathobiology of multiple sclerosis